[{"orgOrder":0,"company":"Starpharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"AUSTRALIA","productType":"Antibody-drug Conjugate","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Starpharma \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Starpharma \/ Merck & Co"},{"orgOrder":0,"company":"Acuitas","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Acuitas","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Acuitas \/ Bayer AG","highestDevelopmentStatusID":"1","companyTruncated":"Acuitas \/ Bayer AG"},{"orgOrder":0,"company":"Cronos Group","sponsor":"Geocann","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Technology","graph2":"Undisclosed","graph3":"Cronos Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cronos Group \/ Geocann","highestDevelopmentStatusID":"1","companyTruncated":"Cronos Group \/ Geocann"},{"orgOrder":0,"company":"Acuitas","sponsor":"GC Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Technology","graph2":"Undisclosed","graph3":"Acuitas","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acuitas \/ GC Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Acuitas \/ GC Biopharma"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"A*STAR's Bioprocessing Technology Institute","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"WuXi Biologics \/ A*STAR's Bioprocessing Technology Institute","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biologics \/ A*STAR's Bioprocessing Technology Institute"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Evariste","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"FINLAND","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orion Corporation \/ Evariste","highestDevelopmentStatusID":"1","companyTruncated":"Orion Corporation \/ Evariste"},{"orgOrder":0,"company":"Cannasoul","sponsor":"Synaptogenix","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Cannasoul","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cannasoul \/ Synaptogenix","highestDevelopmentStatusID":"1","companyTruncated":"Cannasoul \/ Synaptogenix"},{"orgOrder":0,"company":"Luxna Biotech","sponsor":"Summit Pharmaceuticals Europe Srl","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Oligonucleotide","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Luxna Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Luxna Biotech \/ Summit Pharmaceuticals Europe Srl","highestDevelopmentStatusID":"1","companyTruncated":"Luxna Biotech \/ Summit Pharmaceuticals Europe Srl"},{"orgOrder":0,"company":"RevolKa","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"RK007","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"RevolKa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RevolKa \/ Daiichi Sankyo","highestDevelopmentStatusID":"1","companyTruncated":"RevolKa \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Kyowa Pharmaceutical Industry","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Kyowa Pharmaceutical Industry","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kyowa Pharmaceutical Industry \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Kyowa Pharmaceutical Industry \/ Bora Pharmaceuticals"},{"orgOrder":0,"company":"ProteoNic","sponsor":"GigaGen","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"ProteoNic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ProteoNic \/ GigaGen","highestDevelopmentStatusID":"1","companyTruncated":"ProteoNic \/ GigaGen"},{"orgOrder":0,"company":"Belharra Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Belharra Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Belharra Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Belharra Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Collaboration","leadProduct":"Recombinant Human Hyaluronidase PH20 Enzyme","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Halozyme Therapeutics \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Halozyme Therapeutics \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Prime Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"1","companyTruncated":"Prime Medicine \/ J.P. Morgan"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Prime Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"1","companyTruncated":"Prime Medicine \/ J.P. Morgan"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"LNC-Based mRNA Vaccine","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ BioNTech","highestDevelopmentStatusID":"1","companyTruncated":"Matinas BioPharma \/ BioNTech"},{"orgOrder":0,"company":"Kytopen","sponsor":"Mirus Bio","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Kytopen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kytopen \/ Mirus Bio","highestDevelopmentStatusID":"1","companyTruncated":"Kytopen \/ Mirus Bio"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"National Resilience","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ National Resilience","highestDevelopmentStatusID":"1","companyTruncated":"Matinas BioPharma \/ National Resilience"},{"orgOrder":0,"company":"SonoThera","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"SonoThera","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SonoThera \/ ARCH Venture Partners","highestDevelopmentStatusID":"1","companyTruncated":"SonoThera \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Medicinova","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ Sanofi","highestDevelopmentStatusID":"1","companyTruncated":"Medicinova \/ Sanofi"},{"orgOrder":0,"company":"Arzeda","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Arzeda","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arzeda \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Arzeda \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Lindy Biosciences","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Lindy Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lindy Biosciences \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Lindy Biosciences \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"VectorBuilder","sponsor":"Legend Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"VectorBuilder","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VectorBuilder \/ Legend Capital","highestDevelopmentStatusID":"1","companyTruncated":"VectorBuilder \/ Legend Capital"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Drive Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Forge Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forge Biologics \/ Drive Capital","highestDevelopmentStatusID":"1","companyTruncated":"Forge Biologics \/ Drive Capital"},{"orgOrder":0,"company":"Just \u2013 Evotec Biologics","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Just \u2013 Evotec Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Just \u2013 Evotec Biologics \/ Sandoz B2B","highestDevelopmentStatusID":"1","companyTruncated":"Just \u2013 Evotec Biologics \/ Sandoz B2B"},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"Lincoln Park Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Eterna Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eterna Therapeutics \/ Lincoln Park Capital","highestDevelopmentStatusID":"1","companyTruncated":"Eterna Therapeutics \/ Lincoln Park Capital"},{"orgOrder":0,"company":"i2o Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"i2o Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"i2o Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"1","companyTruncated":"i2o Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Unravel Biosciences","sponsor":"Jackson Laboratory","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Unravel Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Unravel Biosciences \/ Jackson Laboratory","highestDevelopmentStatusID":"1","companyTruncated":"Unravel Biosciences \/ Jackson Laboratory"},{"orgOrder":0,"company":"WuXi Advanced Therapies","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"WuXi Advanced Therapies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"WuXi Advanced Therapies \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Advanced Therapies \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"LSA","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oxford Biomedica \/ LSA","highestDevelopmentStatusID":"1","companyTruncated":"Oxford Biomedica \/ LSA"},{"orgOrder":0,"company":"Touchlight","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Licensing Agreement","leadProduct":"mRNA-based Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Technology","graph2":"Undisclosed","graph3":"Touchlight","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Touchlight \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Touchlight \/ Pfizer Inc"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : The collaboration will allow Evariste to utilize its innovative Frobenius Discovery platform to design small-molecule inhibitors for a target selected by Orion.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          December 10, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Undisclosed

                          Sponsor : Evariste

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          Fermion Orion Company Banner

                          02

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Through collaboration, Unravel will utilize the BioNAV drug discovery platform & JAX's extensive expertise in pre-clinical disease modeling to identify potential drugs across multiple diseases.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          September 17, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Undisclosed

                          Sponsor : Jackson Laboratory

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The collaboration will focus on transitioning select innovative medicines from the Novartis portfolio to convenient, self-administered subcutaneous injections using Lindy Bio proprietary technology.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : $20.0 million

                          August 28, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Undisclosed

                          Sponsor : Novartis Pharmaceuticals Corporation

                          Deal Size : $954.0 million

                          Deal Type : Collaboration

                          blank

                          04

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : RevolKa will create and deliver highly functional proteins, RK007, in collaboration with Daiichi Sankyo by using its proprietary protein engineering platform technology, called aiProtein.

                          Product Name : RK007

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          May 27, 2024

                          Lead Product(s) : RK007

                          Therapeutic Area : Technology

                          Highest Development Status : Undisclosed

                          Sponsor : Daiichi Sankyo

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          05

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Matinas’ LNC platform delivery technology offers the potential for next generation intracellular drug delivery beyond lipid nanoparticles and viral vectors with potential advantages across a broad range of therapeutics, including oral bioavailability.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          December 01, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Undisclosed

                          Sponsor : National Resilience

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          06

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The net proceeds will be used to support further development and advancement of Araris’ antibody-drug conjugate candidates using company's proprietary antibody-drug conjugate (ADC)-linker technology.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          November 04, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Undisclosed

                          Sponsor : Samsung Venture Investment Corporation

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank

                          07

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The proceeds will be used to support the development of next-generation mRNA-based therapeutic products and deploying its extensive portfolio of in-licensed mRNA cell engineering patents through strategic partnerships.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 04, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Undisclosed

                          Sponsor : Lincoln Park Capital

                          Deal Size : $10.0 million

                          Deal Type : Agreement

                          blank

                          08

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The partnership sets out highest ambitions for reaching highest quality and lowest cost levels by introducing Just – Evotec Biologics’ data-driven, fully integrated design capability and continuous manufacturing technology (J.DESIGN) into the field o...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          September 05, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Undisclosed

                          Sponsor : Sandoz B2B

                          Deal Size : $640.0 million

                          Deal Type : Partnership

                          blank

                          09

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details :

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          June 06, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Undisclosed

                          Sponsor : Bayer AG

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          10

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The AAV technology was developed by Avigen, which MediciNova acquired in 2009. The milestone payment is the result of the successful achievement of a clinical development milestone for a gene therapy product based on AAV vector technology that is covered...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          April 10, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Undisclosed

                          Sponsor : Sanofi

                          Deal Size : $11.0 million

                          Deal Type : Agreement

                          blank